Trial Profile
A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Spanlecortemlocel (Primary)
- Indications Globoid cell leukodystrophy; Metachromatic leukodystrophy; Mucopolysaccharidosis I
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 05 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 20 Sep 2017 Status changed from withdrawn prior to enrolment to not yet recruiting.
- 22 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment with no patients.